Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Silence Therapeutics

DB:XRP1
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XRP1
DB
£369M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in haematology, cardiovascular, and other rare and metabolic indications. The last earnings update was 209 days ago. More info.


Add to Portfolio Compare Print
  • Silence Therapeutics has significant price volatility in the past 3 months.
XRP1 Share Price and Events
7 Day Returns
-2.3%
DB:XRP1
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
739.3%
DB:XRP1
-7.4%
DE Biotechs
-14.2%
DE Market
XRP1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Silence Therapeutics (XRP1) -2.3% -6.9% 28.6% 739.3% 401.5% 33.6%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • XRP1 outperformed the Biotechs industry which returned -7.4% over the past year.
  • XRP1 outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
XRP1
Industry
5yr Volatility vs Market

XRP1 Value

 Is Silence Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Silence Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €5.12.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Silence Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Silence Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XRP1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in GBP £-0.25
AIM:SLN Share Price ** AIM (2020-04-08) in GBP £4.46
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Silence Therapeutics.

DB:XRP1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SLN Share Price ÷ EPS (both in GBP)

= 4.46 ÷ -0.25

-17.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Silence Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Silence Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Silence Therapeutics's expected growth come at a high price?
Raw Data
DB:XRP1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
89.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Silence Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Silence Therapeutics's assets?
Raw Data
DB:XRP1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in GBP £0.38
AIM:SLN Share Price * AIM (2020-04-08) in GBP £4.46
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:XRP1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SLN Share Price ÷ Book Value per Share (both in GBP)

= 4.46 ÷ 0.38

11.7x

* Primary Listing of Silence Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Silence Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Silence Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Silence Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

XRP1 Future Performance

 How is Silence Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
89.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Silence Therapeutics expected to grow at an attractive rate?
  • Unable to compare Silence Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Silence Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Silence Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:XRP1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XRP1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 89.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XRP1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XRP1 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 9 -16 1
2023-12-31 18 -8 1
2022-12-31 19 -6 1
2021-12-31 23 -2 1
2020-12-31 21 -7 -3 2
2020-04-08
2019-12-31 2 -15 -15 2
DB:XRP1 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-06-30 -18 -18
2019-03-31 -18 -18
2018-12-31 -17 -18
2018-09-30 0 -15 -12
2018-06-30 0 -14 -5
2018-03-31 0 -12 -3
2017-12-31 0 -10 -2
2017-09-30 0 -9 -5
2017-06-30 1 -9 -9
2017-03-31 1 -9 -9
2016-12-31 1 -10 -8
2016-09-30 0 -10 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Silence Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Silence Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XRP1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Silence Therapeutics Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XRP1 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 -0.03 -0.03 -0.03 1.00
2020-12-31 -0.04 -0.03 -0.05 2.00
2020-04-08
2019-12-31 -0.20 -0.19 -0.21 2.00
DB:XRP1 Past Financials Data
Date (Data in GBP Millions) EPS *
2019-06-30 -0.25
2019-03-31 -0.26
2018-12-31 -0.26
2018-09-30 -0.17
2018-06-30 -0.07
2018-03-31 -0.05
2017-12-31 -0.02
2017-09-30 -0.08
2017-06-30 -0.13
2017-03-31 -0.13
2016-12-31 -0.12
2016-09-30 -0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Silence Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Silence Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Silence Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

XRP1 Past Performance

  How has Silence Therapeutics performed over the past 5 years?

  • Silence Therapeutics's last earnings update was 209 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Silence Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Silence Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Silence Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Silence Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Silence Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Silence Therapeutics Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XRP1 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -17.93 10.80 -0.16
2019-03-31 -18.17 10.81 -0.08
2018-12-31 -18.41 10.83
2018-09-30 0.00 -11.60 9.48
2018-06-30 0.00 -4.79 8.12 5.21
2018-03-31 0.01 -3.20 7.29 2.61
2017-12-31 0.02 -1.62 6.46
2017-09-30 0.40 -5.42 5.70
2017-06-30 0.79 -9.22 4.94
2017-03-31 0.78 -8.83 4.45
2016-12-31 0.77 -8.44 3.97
2016-09-30 0.39 -7.84 3.65
2016-06-30 -7.24 3.34
2016-03-31 -6.94 3.00
2015-12-31 -6.65 2.66
2015-09-30 0.00 -8.13 2.74
2015-06-30 0.01 -9.61 2.82
2015-03-31 0.01 -10.35 3.04
2014-12-31 0.02 -11.09 3.26
2014-09-30 0.05 -11.15 3.61
2014-06-30 0.08 -11.22 3.96
2014-03-31 0.10 -10.11 3.75
2013-12-31 0.12 -9.00 3.54
2013-09-30 0.14 -7.58 3.20
2013-06-30 0.17 -6.16 2.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Silence Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Silence Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Silence Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Silence Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Silence Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

XRP1 Health

 How is Silence Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Silence Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Silence Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Silence Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Silence Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Silence Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Silence Therapeutics Company Filings, last reported 9 months ago.

DB:XRP1 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 27.16 0.00 16.51
2019-03-31 27.16 0.00 16.51
2018-12-31 35.06 0.00 26.54
2018-09-30 35.06 0.00 26.54
2018-06-30 43.96 0.00 34.34
2018-03-31 43.96 0.00 34.34
2017-12-31 52.35 0.00 43.06
2017-09-30 52.35 0.00 43.06
2017-06-30 48.54 0.00 29.85
2017-03-31 48.54 0.00 29.85
2016-12-31 54.18 0.00 39.02
2016-09-30 54.18 0.00 39.02
2016-06-30 57.47 0.00 47.60
2016-03-31 57.47 0.00 47.60
2015-12-31 60.43 0.00 51.91
2015-09-30 60.43 0.00 51.91
2015-06-30 62.07 0.00 55.77
2015-03-31 62.07 0.00 55.77
2014-12-31 27.76 0.00 21.86
2014-09-30 27.76 0.00 21.86
2014-06-30 33.13 0.00 26.30
2014-03-31 33.13 0.00 26.30
2013-12-31 27.58 0.00 20.89
2013-09-30 27.58 0.00 20.89
2013-06-30 32.46 0.00 24.72
  • Silence Therapeutics has no debt.
  • Silence Therapeutics has not taken on any debt in the past 5 years.
  • Silence Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • Silence Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Silence Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Silence Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

XRP1 Dividends

 What is Silence Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Silence Therapeutics dividends. Estimated to be 0.78% next year.
If you bought €2,000 of Silence Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Silence Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Silence Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XRP1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XRP1 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.04 1.00
2020-12-31 0.03 1.00
2020-04-08
2019-12-31 0.02 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Silence Therapeutics has not reported any payouts.
  • Unable to verify if Silence Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Silence Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Silence Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Silence Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Silence Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Silence Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Silence Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

XRP1 Management

 What is the CEO of Silence Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Silence Therapeutics has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Silence Therapeutics management team in years:

1.1
Average Tenure
  • The average tenure for the Silence Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Iain Ross

TITLE
Executive Chairman
AGE
65
TENURE
0.3 yrs

Rob Quinn

TITLE
CFO & Secretary
TENURE
1.3 yrs

Barbara Ruskin

TITLE
Senior VP

Linnea Elrington

TITLE
VP & Head of Human Resources
TENURE
2.4 yrs

Mark Cameron

TITLE
Head of Chemistry
TENURE
3.9 yrs

Richard Jenkins

TITLE
Head of Clinical Development
TENURE
1.8 yrs

Giles Campion

TITLE
Head of R&D and Chief Medical Officer
AGE
65
TENURE
0.8 yrs

John Strafford

TITLE
VP & Head of Business Development
TENURE
0.9 yrs

Jørgen Wittendorff

TITLE
Senior VP & Head of Manufacturing
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Silence Therapeutics board of directors in years:

0.2
Average Tenure
62.5
Average Age
  • The average tenure for the Silence Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Iain Ross

TITLE
Executive Chairman
AGE
65
TENURE
1 yrs

Dave Lemus

TITLE
Senior Independent Director
COMPENSATION
£25K
AGE
56
TENURE
0.3 yrs

Gordon Duff

TITLE
Chairman of Scientific Advisory Board
TENURE
0.2 yrs

Alistair Gray

TITLE
Senior Independent Non-Executive Director
COMPENSATION
£50K
AGE
71
TENURE
0.3 yrs

James Ede-Golightly

TITLE
Non-Executive Director
AGE
39
TENURE
1 yrs

Steven Romano

TITLE
Non-Executive Director
AGE
60
TENURE
0.8 yrs

John Porter

TITLE
Member of Scientific Advisory Board
TENURE
0.2 yrs

Henry Ginsberg

TITLE
Member of Scientific Advisory Board
TENURE
0.2 yrs

Art Levin

TITLE
Member of Scientific Advisory Board
AGE
65
TENURE
0.2 yrs

Annemieke Aartsma-Rus

TITLE
Member of Scientific Advisory Board
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Oct 19 Buy David Lemus Individual 04. Oct 19 04. Oct 19 4,000 €2.09 €8,341
03. Oct 19 Buy Alistair Gray Individual 02. Oct 19 02. Oct 19 3,171 €2.12 €6,734
30. Sep 19 Buy Iain Ross Individual 30. Sep 19 30. Sep 19 25,000 €2.12 €53,015
02. Oct 19 Buy Steven Romano Individual 02. Oct 19 02. Oct 19 10,000 €2.17 €21,685
X
Management checks
We assess Silence Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Silence Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

XRP1 News

Simply Wall St News

XRP1 Company Info

Description

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in haematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; and SLN360 for the reduction of cardiovascular risk, and prevention of heart attacks and cardiovascular diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Details
Name: Silence Therapeutics plc
XRP1
Exchange: DB
Founded:
£417,963,978
82,676,845
Website: http://www.silence-therapeutics.com
Address: Silence Therapeutics plc
72 Hammersmith Road,
London,
Greater London, W14 8TH,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SLN Ordinary Shares London Stock Exchange AIM Market GB GBP 18. Apr 1995
OTCPK SLNC.F Ordinary Shares Pink Sheets LLC US USD 18. Apr 1995
DB XRP1 Ordinary Shares Deutsche Boerse AG DE EUR 18. Apr 1995
Number of employees
Current staff
Staff numbers
45
Silence Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 20:43
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2019/09/12
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.